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Abstract: We report herein the synthesis, the biological evaluation and the docking analysis of a class of 
COX-2 inhibitors endowed with NO-releasing properties. Some of the synthesized compounds displayed 
good activities towards COX-2, as well as vasorelaxing properties due to NO release. Overall, they exhibited 
a good in vivo pharmacological profile and proved to be able to reduce writhes in a murine model of 
inflammatory pain. Derivative 2b showed an outstanding activity, with an efficacy comparable to that of 
celecoxib even at very low concentrations.  
 
Introduction 
Conventional non-steroidal anti-inflammatory drugs (NSAIDs) are widely used for treating different 
pathological conditions, from small injuries, headache or fever to chronic and severe pain. The efficacy of 
this class of drugs in relieving inflammation is related to their capability to inhibit Cyclooxygenase (COX) 
enzymes, thus preventing the production of prostaglandins from arachidonic acid. While the therapeutic 
effects are primarily mediated by Cyclooxygenase-2 (COX-2) inhibition, the inhibition of Cyclooxygenase-1 
(COX-1) is responsible for NSAIDs side effects, including renal and gastrointestinal (GI) toxicities. For this 
reason, a class of drugs that selectively inhibit the COX-2 isoform (coxibs) has been developed and 
marketed[1,2]. However, the complete inhibition of COX-2 has led to a lack of a balance in the prostanoid 
production at cardiovascular (CV) level and as a consequence, the long-term administration of coxibs 
caused to many patients an increased incidence of thrombotic events and a greater CV hazard[3–6]. 
Therefore, different strategies have been adopted to obtain safer anti-inflammatory agents, endowed with 
spare gastrointestinal and cardiovascular toxicity[7,8]. A valuable option is that of designing multitarget-
directed ligands, combining in the same scaffold pharmacophoric elements able to simultaneously 
modulate different targets, in order either to reduce side effects or enhance the anti-inflammatory 
activity[9]. Dual fatty acid amide hydrolase (FAAH)/COX inhibitors are a representative example of this class 
of drugs[10].  
Another interesting strategy to reduce the side effects due to COX inhibition is that of developing 
“molecular hybrids” conjugating the COX-inhibiting scaffold with a moiety able to counteract side-effects, 
such as a nitric oxide (NO) releasing group[11,12]. NO is a small endogenous gasotrasmitter produced by 
three isozymes (NOS, NO synthases) in a large number of cells and plays a pivotal role in blood pressure 
regulation, cell proliferation, vascular homeostasis and vasorelaxant processes[13,14]. Due to its small size 
and to its very high reactivity, it serves as a potent local modulator that rapidly diffuses through 
membranes to target cells and it is involved in cell-to-cell communication[15]. In the CV system it acts as a 
physiological vasodilator and mediates smooth muscle relaxation by modulating the soluble Guanylyl 
Cyclase-Cyclic Guanosine monophosphate (sGC-cGMP) pathway[16]. It also inhibits platelet aggregation 
and is likely to prevent both early and later steps of atherogenosis by reducing leucocyte adhesion to the 
vascular wall[17]. In addition, it can regulate gastric blood flow and contribute to gastric mucosal defence 
by modulating mucus and bicarbonate secretion[18]. The first example of COX-inhibiting nitric oxide donors 
(CINODs) is Naproxcinod (AZD3582, produced by NicOx), resulting from the conjugation of a NO-releasing 
moiety to a NSAID scaffold[12] (Fig.1). Hereafter, given the key role of NO at CV level, such strategy was 
applied to COX-2-selective inhibitors, in order to obtain more potent anti-inflammatory agents with an 
abated GI toxicity and an acceptable CV safety profile[19–23].  
  
 
Figure 1. Chemical structure of Naproxcinod. 
 
 
In this context, our research group developed a number of selective COX-2 inhibitors nitric oxide donors by 
conjugating a diaryl-pyrrole scaffold endowed with selective COX-2 inhibition properties[24–32] with 
different nitrooxyalkyl side chains, such as esters, α-amino esters, amides, α-amino amides, ethers, β-amino 
ethers, inverse esters and amides[33–37]. Such medicinal chemistry program led to the identification of 
very promising candidates (Fig. 2), with high in vitro potencies (COX-2 inhibition at 10 µM ≥ 96%), a great 
efficacy in determining NO-vasorelaxing responses and a good antinociceptive activity in the abdominal 
writhing test (% of writhes reduction between 46 and 77 at 10 mg/kg).  
   
 Figure 2. Chemical structures of the most promising compounds previously synthesized. 
 
To complete the picture, we present herein the development of a new class of sulphamoyl pyrroles as COX-
2 inhibitors NO donors. Indeed, assuming that the lower logP of arylsulphonamides could contribute to 
improved bioavailability and absorption with respect to arylsulphones, we explored the replacement of the 
methylsulphonyl moiety with a sulfamoyl one, to further improve in vivo activity[31,38]. Thus, we prepared 
the nitrooxy acetic esters and amides 1-2 bearing a C5 sulphamoylphenyl group and a fluorinated N1 
phenyl ring, according to Structure Activity Relationship (SAR) data emerged from the previously 
synthesized compounds. Finally, considering that such compounds are subjected to in vivo metabolism and 
that they could be in turn converted into the corresponding alcohols after NO release, the hydroxyl-
derivatives 3-4 were synthesized and tested as probable metabolites (Fig.3).  
 
  
Figure 3. Chemical structures of compounds 1-4. 
 
 
 
 
 
Results and Discussion 
Chemistry 
Compounds 1-4 were prepared following the synthetic pathway described in Scheme 1. The acetic acid 
derivatives 5a,b were synthesized according to the previously reported procedure[31]. Briefly, derivatives 
1-3 were obtained through a coupling reaction between 2-hydroxyethyl nitrate, 2-aminoethyl nitrate or 
ethylene glycol and the suitable acid 5a,b in the presence of DMAP, EDCi and TEA. On the other hand, the 
hydroxyl derivatives 4a,b were obtained via an EDCi/HOBt coupling stage.  
 
  
 
Scheme 1. Synthesis of compounds 1-4. 
 
 
 
 
In vitro studies 
 
Inhibition of COX-1/COX-2 was assessed through an enzyme immunoassay and the prostanoids were 
quantified using the commercially available COX Inhibitor Screening Assay (Cayman Chemical Company, 
Ann Arbor, MI, USA). Data are reported as % of inhibition for all the tested compounds and as IC50 for the 
two most active ones (1a and 1b, Table 1).  
 
 
Table 1. In vitro activities of compounds 1-4 and Dup-697 used as reference compound towards COX-1 and 
COX-2. 
Table 1. In vitro activities of compounds 1-4 and Dup-697 used as reference compound 
towards COX-1 and COX-2. 
 
Compound 
COX-1 % of inhibition 
(10 µM)[a] 
 COX-2 % of inhibition 
(10 µM)[a] 
IC50 COX-2 (µM)[d] 
1a 
 
n.a[b] 86 1.17±0.06 
1b 
 
n.a[b] 89 0.41±0.01 
2a 
 
n.t[c] 16 n.d.[e] 
2b 
 
n.t[c] 45 n.d.[e] 
3a 
 
n.t[c] 16 n.d.[e] 
3b 
 
n.t[c] n.a[b] n.d.[e] 
4a 
 
n.t[c] 18 n.d.[e] 
4b 
 
n.t[c] 15 n.d.[e] 
Dup-697 - 100 - 
[a] Each value is the mean of at least three determination, carried out in triplicate. SEM ≤5%. 
[b] Not active: no inhibition was observed at 10 µM of tested compound. [c] Not tested.[d] 
IC50 values, means±SD, represent the concentration required to produce 50% enzyme 
inhibition. [e] Not determined. 
 
 
As reported in Table 1, nitrated acetic esters 1a,b displayed the best activities against COX-2, with IC50 
values of 1.17±0.06 and 0.41±0.01, respectively. Such derivatives were found to be much more active than 
the corresponding hydroxyl derivatives 3a,b, confirming the same trend observed for the methylsulphonyl 
analogues[33]. On the other hand, the presence of the amide fragment was responsible for a drop in 
activity; in fact, both the acetic amides 2a and 2b proved to be less active than the corresponding acetic 
esters, proving that the combination of a nitroxyalkyl chain with an ester moiety guarantees the best 
interactions within the binding site. 
 
 
 
 
 
 
  
Ex vivo NO releasing studies 
 
The capability of nitrooxy derivatives 1-2 in determining vasorelaxing responses was assessed using rat 
endothelium-denuded aortic rings precontracted with 30 mM KCl as an experimental model of vascular 
smooth muscle. Since NO induces vasodilator responses by activating GC and consequently increasing 
cGMP levels, the experiments were also performed in the presence of a GC inhibitor (1H-
[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one, ODQ), to confirm their mechanism of action. As reported in Table 
2, all the tested compounds proved to be effective in inducing vasorelaxing responses. In particular, the 
nitrooxy amides 2a,b showed the best activity, with values of efficacy (Emax) and potency (pIC50) 
comparable to that of Naproxcinod, used as a control. Moreover, all the tested compounds were found to 
be inactive in the presence of ODQ, proving that their efficacy was due to NO release. Notably, no 
vasorelaxing effect was observed at low concentrations, suggesting that these compounds gradually release 
NO (Fig. 4); as a consequence, they are not supposed to be responsible for a massive hypotensive effect in 
vivo, that is an essential feature for hybrid drugs.   
Table 2. Nitric oxide releasing efficacy and potency for compounds 1-2 and Naproxcinod used as 
reference compound. The vasorelaxing efficacy was evaluated as the maximal vasorelaxing 
response (Emax), expressed as a percentage of the contractile tone induced by KCl 30 mM. The 
potency was expressed as pIC50 that was calculated as negative logarithm of the molar 
concentration of the tested compounds evoking a half reduction of the contractile tone induced by 
KCl 30 mM.  
 
Compound Emax pIC50 + ODQ 1 μM 
1a 47±0.5 n.c[a] + 
1b 59.1±0.4 5.55±0.07 + 
2a 74.9±2.5 5.82±0.04 + 
2b 67.5±2.3 5.49±0.00 + 
Naproxcinod 68.0±3.0 6.33±0.06 + 
[a] Not calculated. 
 
   
 
  
Figure 4. Concentration-response curve for the vasorelaxing effects exerted by compounds 1-2. The 
experiments were performed both in the presence (control, black triangles) and in the absence (red 
squares) of 1 μM ODQ. The vertical bars indicate the standard error. 
In vivo studies: writhes reduction in the acetic acid-induced abdominal constrictions in mice.  
Based on their in vitro potencies, compounds 1-2 and 4b were selected to assess their analgesic efficacy in 
a murine model of inflammatory pain. Such derivatives were orally administered 30 minutes before 
inducing writhes by means of an acetic acid intraperitoneal injection. Afterward, the number of writhes was 
measured and the results were expressed as a percentage of writhes reduction with respect to the vehicle-
treated mice (Table 3). All the tested compounds proved to be effective in reducing the number of writhes. 
However, the nitrooxy amides 2a,b exhibited a better pharmacological profile with respect to the acetic 
esters, differently from what emerged from the in vitro results. Indeed, the acetic esters 1a,b were almost 
inactive at low doses, showing an appreciable efficacy only when administered at doses higher than 10 
mg/kg. Interestingly, acetic ester 1b was as active as the methylsulphonyl analogue MAB 103 only in the 20 
mg/kg range (MAB 103 % of writhes inhibition at 20 mg/kg= 47.5), while it was even active at 10 mg/kg 
(MAB 103 is inactive below 20 mg/kg)[33]. On the other hand, the acetic amides showed good activities 
also in the 1-10 mg/kg range, probably because they are endowed with both a greater solubility and a 
higher stability, as previously demonstrated for the methylsulphonyl analogues[37]. Therefore, their 
improved pharmacokinetic properties might counterbalance the lower affinity for the enzyme. Derivative 
2b exhibited a unique profile: being the most active one in the 3-10 mg/kg range, its efficacy was also 
evaluated at lower doses and it proved to be significantly effective even at 1 mg/kg (35% of writhes 
reduction), with an efficacy comparable to that of celecoxib and better than that of the methylsulphonyl 
analogue MAB137 (inactive below 3 mg/kg)[37]. Finally, the hydroxyl compound 4b was found to be less 
active than the corresponding nitrooxyl analogue, confirming the trend observed for the previously 
synthesized compounds.  
Table 3. Effects of 1-2, 4b and celecoxib in the mouse abdominal constriction test (acetic acid 0.6%). 
Table 3. Effects of 1-2, 4b and celecoxib in the mouse abdominal constriction test (acetic 
acid 0.6%). 
Treatment No. of mice Dose (mg/kg 
po) 
No.of writhes Writhes 
reduction (%) 
CMC 28 - 33.6±2.2 - 
1a 
 
1a 
5 
 
6 
10 
 
30 
27.6±3.5 
 
19.0±2.9 
17.8 
 
43.4 
1b 
 
1b 
 
1b 
10 
 
10 
 
8 
5 
 
10 
 
20 
30.6±3.7 
 
18.9±3.0* 
 
17.8±3.4* 
8.9 
 
43.7 
 
47.0  
2a 
 
2a 
 
2a 
 
2a 
10 
 
10 
 
8 
 
9 
5 
 
10 
 
20 
 
40 
26.7±3.3 
 
18.5±4.2* 
 
15.8±3.7* 
 
16.7±2.5* 
20.5 
 
44.9 
 
53.0 
 
50.3 
2b 
 
2b 
 
2b 
5 
 
5 
 
6 
1 
 
3 
 
10 
21.8±3.5* 
 
19.4±2.9* 
 
16.7±3.5* 
35.1 
 
42.3 
 
50.3  
4b 
 
4b 
 
4b 
7 
 
8 
 
6 
3 
 
10 
 
30 
26.4±2.5˄ 
 
23.8±3.1 
 
21.2±2.7* 
21.4 
 
29.2 
 
36.9 
celecoxib 
 
celecoxib 
 
celecoxib 
 
celecoxib 
 
celecoxib 
10 
 
10 
 
10 
 
10 
 
10 
 
 
1 
 
5 
 
10 
 
20 
 
40 
 
19.3±2.5 
 
16.6±2.2 
 
14.2±2.3 
 
13.9±2.7 
 
10.2±2.1 
 
 
42.5 
 
50.6 
 
57.7 
 
58.6 
 
69.6 
 
 
All drugs were administered per os 30 min before test ˄P<0.05; *P<0.01 versus vehicle treated mice. 
 
  Structure-based studies 
As previously reported, Vina showed the most suitable docking program to study the binding mode of COX-
2 inhibitors[31]. Therefore, the newly synthesized compounds were all cross-docked by means of this 
program. In particular, compounds were modeled and cross-docked into all the available COX-2 
experimental structures following the docking protocol previously reported[31]. The lowest energy poses 
were selected as the likely binding modes for the newly synthesized compounds. In general the new 
derivatives were found to dock into COX-2 similarly to the previously reported compounds[31]. To avoid 
redundancy the herein binding mode description focused on the most in vivo active compound 2b (see 
Table 3), which was found able to inhibit COX-2 (see Table 1). The lowest energy docked pose of 2b was 
found in the celecoxib/COX-2 experimental complex (pdb entry code 3LNI) displaying a binding mode highly 
superimposable to that of the reference compound (Fig. 5). The three aromatic portions of the two 
compounds are highly overlapped and only small differences are visible for the 3-fluorophenyl group of  2b 
and the 4-methylphenyl group of celecoxib, being the former slightly rotated of about 30 degrees to allow 
accommodation of the 3-fluoro substituent. Differently from celecoxib, the 2b side chain fills a pocket 
formed mainly by hydrophobic residues (Met113, Val116, Leu117, Val344, Ile345, Val349, Leu359, Ser530, 
Leu531 and Leu534) and a moderate hydrogen bond distance is observable among the distal nitro group 
and the Ser530 side chain hydroxyl (Ser513-NO2•••HOSer513= 3.02 Å). 
  
Figure 5. Docked proposed 2b (gray colored carbon atoms) binding mode into 3LNI binding site. For 
comparison purpose, the co-crystallized celecoxib is also depicted (light magenta colored carbon atoms). 
The figure was generated by means of UCSF Chimera 1.10.2. The surface of Met113, Val116, Leu117, 
Val344, Ile345, Val349, Leu359, Ser530, Leu531 and Leu534 residues is displayed to highlight the 2b side 
chain binding pocket. 
 
Conclusions 
We reported the further structural modification of a series of pharmacodynamic hybrids based on a 1,5-
diarylpyrrole scaffold. Some of the newly synthesized compounds were endowed with a good affinity for 
COX-2, proving that the replacement of methylsulphonylphenyl moiety at the C5 of the pyrrole ring does 
not significantly affect the affinity for the target enzyme. The nitrooxyl derivatives 1-2 also exhibited good 
vasorelaxing properties, due to NO release. Overall, the tested compounds exhibited a good in vivo 
pharmacological profile and they all proved to be able to reduce writhes in a murine model of inflammatory 
pain. In particular, derivative 2b is characterized by an outstanding in vivo potency and proved to be 
effective even at 1 mg/kg, showing a lower effective dose with respect to the most potent methylsulphonyl 
analogue previously synthesized MAB 137. Structure-based studies confirmed that it docks into COX-2 
adopting a conformation highly superimposable to that of celecoxib, used as a reference compound. Being 
the most promising derivative of this class, further studies will be addressed to assess its pharmacokinetic 
profile and to evaluate which is the actual contribution of the sulphamoyl moiety to its solubility and to its 
bioavailability. 
Experimental Section 
Chemistry 
All chemicals used were of reagent grade. Yields refer to purified products and are not optimized. Melting 
points were determined in open capillaries on a Gallenkamp apparatus and were uncorrected. Sigma–
Aldrich silica gel 60 (230–400 mesh) was used for column chromatography. Merck TLC plates (silica gel 60 F 
254) were used for thin-layer chromatography (TLC). 13C NMR and 1H NMR spectra were recorded with a 
Bruker AC 400 spectrometer in the indicated solvent (TMS as the internal standard). The values of the 
chemical shifts are expressed in δ. Mass spectra were recorded on an API-TOF Mariner by Perspective 
Biosystem (Stratford, Texas, USA). Compound purity was assessed by elemental analysis obtained with a PE 
2400 analyzer (PerkinElmer). The purity of target compounds was >95%. 
General procedure for the preparation of nitrooxyalkyl and hydroxyalkyl esters 1a,b and 3 a,b.  
To a solution of the appropriate acid (5 a,b) (0.200 g, 0.54 mmol) in  a mixture of DCM / DMF 10:1 (v/v) (7 
mL), the suitable alcohol (0.8 mmol), DMAP (0.109 g, 0.65 mmol), EDCi (0.106 g, 0.87 mmol) and TEA (0.11 
mL, 0.65 mmol) were added in sequence under a nitrogen atmosphere. The reaction was quenched after 15 
h with water (10 mL) and extracted with DCM (50 mL X 3). The organic layer was washed with 1 N HCl (50 
mL), NaHCO3 saturated solution (50 mL), brine (50 mL) and dried over Na2SO4. The organic phase was then 
filtrated and concentrated under reduced pressure to give a crude product that was purifyed on silica gel 
using a mixture of cyclohexane/ethyl acetate 2:1 (v/v) as eluent to give derivatives 1a,b and 3 a,b as 
yellowish and white powders, respectively.  
2-(Nitrooxy)ethyl 2-(1-(4-fluorophenyl)-2-methyl-5-(4-sulfamoylphenyl)-1H-pyrrol-3-yl)acetate (1a): 
Yellowish powder, (0.162 g, 63% yield); mp 109 °C; 1H NMR (400 MHz CDCl3) δ (ppm) = 2.05 (s, 3 H, CH3 
pyrrolic), 3.51 (s, 2H, C-CH2-CO), 4.43 (t, J=3.18 Hz, 2 H, CO-O-CH2-CH2-ONO2), 4.75 (t, J=3.18 Hz, 2 H, CO-
O-CH2-CH2-ONO2), 4.78 (s broad, 2 H, SO2NH2), 6.48 (s, 1H, CH pyrrolic), 7.17-7.28 (m, 6H, H aromatic), 
7.68 (d, J=7.34 Hz, 2H, H aromatic); 13C-NMR (100 MHz, CDCl3) δ (ppm): 169.5, 158.8, 146.6, 143.4, 142.5, 
134.9, 127.8, 126.4, 123.1, 122.6, 121.8, 117.0, 114.4, 66.2, 62.3, 34.8, 10.3; IR (KBr): ν˜=3390, 3300, 1752, 
1630 cm−1; ESI-Mass: m/z 500.09 [M + Na]+; HRMS-FAB m/z [M+H]+ calcd for C21H20FN3O7S: 477.1006, 
found: 477.1003; Anal. calcd for C21H20FN3O7S: C 52.83, H 4.22, N 8.80, O 23.46, found: C 52.80, H 4.25, N 
8.82, O 23.47. 
2-(Nitrooxy)ethyl 2-(1-(3-fluorophenyl)-2-methyl-5-(4-sulfamoylphenyl)-1H-pyrrol-3-yl)acetate (1b): 
Yellowish powder, (0.149 g, 58% yield); mp 102 °C; 1H NMR (400 MHz CDCl3) δ (ppm) = 2.09 (s, 3 H, CH3 
pyrrolic), 3.55 (s, 2 H, C-CH2-CO), 4.43 (t, J=3.18 Hz, 2 H, CO-CH2-CH2-ONO2 ), 4.71 (t, J=3.18 Hz, 2 H, CO-
CH2-CH2-ONO2), 4.75 (s broad, 2 H, SO2NH2), 6.48 (s, 1H, CH pyrrolic), 6.90 (d, J=7.34 Hz, 1H, H aromatic), 
6.96 (d, J=7.34 Hz, 1H, H aromatic), 7.07-7.19 (m, 3H, H aromatic), 7.39-7.37 (m, 1H, H aromatic), 7.68 (d, 
J=7.34 Hz, 2H, H aromatic); 13C-NMR (100 MHz, CDCl3) δ (ppm): 169.5, 163.8, 144.6, 143.4, 142.5, 134.9, 
131.2, 127.5, 127.0, 126.4, 122.6, 117.0, 114.4, 111.1, 106.5, 69.2, 62.3, 34.8, 10.3; IR (KBr): ν˜=3366, 3255, 
1749, 1620 cm−1; ESI-Mass: m/z 500.09 [M + Na]+; HRMS-FAB m/z [M+H]+ calcd for C21H20FN3O7S: 
477.1006, found: 477.1003; Anal. calcd for C21H20FN3O7S: C 52.83, H 4.22, N 8.80, O 23.46 found: C 52.80, 
H 4.25, N 8.78, O 23.47. 
2-Hydroxyethyl 2-(1-(4-fluorophenyl)-2-methyl-5-(4-sulfamoylphenyl)-1H-pyrrol-3-yl)acetate (3a): White 
powder, (0.107 g, 43% yield); mp 131 °C; 1H NMR (400 MHz, DMSO-d6) δ ppm 1.98 (s, 3H, CH3 pyrrolic), 
3.50 (s, 2H, C-CH2-CO), 3.58 (t, J= 3.20 Hz, 2H, CO-O-CH2-CH2-OH), 4.05 (t, J= 3.20 Hz, 2H, CO-O-CH2-CH2-
OH), 4.81 (s broad, 1H, OH), 6.46 (s, 1H, CH pyrrolic), 7.11 (d, J=8.07 Hz, 2H, H aromatic) 7.22-7.27 (m, 6H, H 
aromatic and SO2NH2), 7.57 (d, J=8.07 Hz, 2H, H aromatic); 13C-NMR (100 MHz, DMSO-d6) δ (ppm): 169.5, 
158.8, 146.6, 143.4, 142.5, 134.9, 127.8, 126.4, 123.1, 122.6, 121.8, 117.0, 114.4, 66.2, 62.3, 34.8, 10.3; IR 
(KBr): ν˜=3350, 3256, 1760 cm−1; ESI-Mass: m/z 455.10 [M + Na]+; HRMS-FAB m/z [M+H]+ calcd for 
C21H21FN2O5S: 432.1155, found: 432.1150; Anal. calcd for C21H21FN2O5S: C 58.32, H 4.89, N, 6.48, O 
18.50 found: C 58.35, H 4.91, N, 6.53, O 18.45. 
2-Hydroxyethyl 2-(1-(3-fluorophenyl)-2-methyl-5-(4-sulfamoylphenyl)-1H-pyrrol-3-yl)acetate (3b): White 
powder, (0.107 g, 46% yield); mp 121 °C; 1H NMR (400 MHz, DMSO-d6) δ (ppm) = 2.01 (s, 3H, CH3 pyrrolic), 
3.50 (s, 2H, C-CH2-CO), 3.58 (t, J = 3.16 Hz, 2H, CO-O-CH2-CH2-OH), 4.06 (t, J = 3.16 Hz, 2H, CO-O-CH2-CH2-
OH), 4.81 (s broad, 1H, OH), 6.48 (s, 1H, CH pyrrolic), 7.01 (d, J=7.37 Hz, 1H, H aromatic) 7.12 (d, J=7.37 Hz, 
2H, H aromatic), 7.25-7.30 (m, 4H, H aromatic and SO2NH2), 7.41-7.45 (m, 1H, H aromatic), 7.51 (d, J=7.37 
Hz, 2H, H aromatic); 13C-NMR (100 MHz, DMSO-d6) δ (ppm): 169.5, 158.8, 146.6, 143.4, 142.5, 134.9, 
131.7, 127.8, 126.4, 123.1, 121.8, 117.0, 114.4, 11.8, 108.5, 66.2, 62.3, 34.8, 10.3; R (KBr): ν˜= IR (KBr): 
ν˜=3383, 3350, 1765 cm−1; ESI-Mass: m/z 455.10 [M + Na]+; HRMS-FAB m/z [M+H]+ calcd for 
C21H21FN2O5S: 432.1155, found: 432.1159; Anal. calcd for C21H21FN2O5S: C 58.32, H 4.14, N 6.48, O 
18.76 found: C 58.35, H 4.20, N 6.45, O 18.73. 
General procedure for the preparation of nitrooxyalkyl amides 2a,b. 
2-aminoethylnitrate salt (0.203 g, 1.2 mmol), DMAP (0.164 g, 0.97 mmol) and EDCI (0.159 g, 1.3 mmol) 
were added in sequence to a solution of the acid partner (5a,b) (0.300 g, 0.81 mmol) dissolved in a mixture 
of DCM/DMF 10:1 (v/v) (10 mL), under a nitrogen flow. An excess of TEA (0.17 mL, 1.3 mmol) was then 
added dropwise and the reaction was stirred at rt for 12 h. The mixture was then quenched with water (10 
mL) and extracted with DCM (50 mL X 3). The organic layer was washed with 1 N HCl (50 mL), NaHCO3 
saturated solution (50 mL), brine (50 mL) and dried over Na2SO4. After filtration and concentration of the 
organic phase a crude material was obtained and was purified by chromatography on silica gel using as 
eluent a mixture of cyclohexane/ethyl acetate 1:1 (v/v), affording compounds 2a,b as yellowish powders. 
2-(2-(1-(4-Fluorophenyl)-2-methyl-5-(4-sulfamoylphenyl)-1H-pyrrol-3-yl)acetamido)ethyl nitrate (2a): 
Yellowish powder, (0.237 g, 50 % yield); mp 127°C ; 1H NMR (400 MHz, DMSO-d6) δ ppm 1.97 (s, 3H, CH3 
pyrrolic), 3.26 (s, 2H, C-CH2-CO) 3.37 (t, J=5.01 Hz, 2 H, CO-NH-CH2-CH2-ONO2), 4.54 (t, J=5.01 Hz, 2H, CO-
NH-CH2-CH2-ONO2), 6.43 (s, 1H, CH pyrrolic), 7.09 (d, J=8.07 Hz, 2H, H aromatic), 7.21-7.29 (m, 6H, 
aromatic and SO2NH2), 7.56 (d, J=8.07 Hz, 2H, H aromatic), 8.11 (s broad, 1H, CONH); 13C-NMR (100 MHz, 
DMSO-d6 ) δ (ppm) = 169.5, 158.8, 146.6, 143.4, 142.5, 134.9, 127.8, 126.4, 123.1, 122.6, 121.8, 117.0, 
114.4, 72.5, 36.2, 34.8, 10.3; IR (KBr): ν˜=2967, 2923, 1735, 1637 cm−1; ESI-Mass: m/z 499.11 [M + Na]+; 
HRMS-FAB m/z [M+H]+ calcd for C21H21FN4O6S: 477.1166, found: 477.1158; Anal. calcd for: 
C21H21FN4O6S: C 52.94, H 4.44, N 11.76, O 20.15, found: C 53.00, H 4.43, N 11.70, O 20.13.  
2-(2-(1-(3-Fluorophenyl)-2-methyl-5-(4-sulfamoylphenyl)-1H-pyrrol-3-yl)acetamido)ethyl nitrate (2b): 
Yellowish powder, (0.242 g, 51 % yield); mp 125°C; 1H NMR (400 MHz, DMSO-d6) δ (ppm) = 2.03 (s, 3H, 
CH3 pyrrolic), 3.28 (s, 2H, C-CH2-CO), 3.43 (t, J=5.14 Hz, 2H, CO-NH-CH2-CH2-ONO2), 4.57 (t, J=5.14 Hz, 2H, 
CO-NH-CH2-CH2-ONO2), 6.46 (s, 1H, CH pyrrolic) 7.02 (d, J=8.31 Hz, 1H, H aromatic), 7.13 (d, J=8.31 Hz, 2 H, 
H aromatic), 7.18-7.33 (m, 4H, H aromatic and SO2NH2 ), 7.51-7.57 (m, 1 H, H aromatic), 7.61 (d, J=8.31 Hz, 
2H, H aromatic), 8.15 (s broad, 1H, CONH); 13C-NMR (100 MHz, DMSO-d6) δ (ppm): 169.5, 158.8, 146.6, 
143.4, 142.5, 134.9, 131.6, 127.8, 126.3, 125.2, 121.4, 117.0, 114.4, 109.4, 11.9, 76.2, 37.3, 34.8, 10.3. IR 
(KBr): ν˜=3182, 3079, 1731, 1635 cm−1; ESI-Mass: m/z 499.11 [M + Na]+; HRMS-FAB m/z [M+H]+ calcd for: 
477.1166, found: 477.1158; Anal. calcd for: C21H21FN4O6S: C 52.94, H 4.44, N 11.76, O 20.15, found: C 
53.00, H 4.43, N 11.83, O 20.13.  
General procedure for the preparation of hydroxyalkyl amides 4a,b. 
Ethanolamine (0.067 g, 1.1 mmol), HOBt (0.168 g, 1.1 mmol), and EDCi (0.159 g, 1.3 mmol) were added in 
sequence to a solution of the suitable 1,5-diarylpyrrole-3-acetic acid (5a,b) (0.300 g, 0.8 mmol) in a mixture 
of DCM/DMF 10:1 (v/v) (10 mL), under a nitrogen atmosphere. An excess of TEA (0.17 mL, 1.3 mmol) was 
then added dropwise and the reaction was stirred at rt. After 12 h, the mixture was quenched with water 
(10 mL) and extracted with DCM (50 mL X 3). The organic layer was washed with 1 N HCl (50 mL), NaHCO3 
saturated solution (50 mL), brine (50 mL) and dried over Na2SO4. After filtration and concentration of the 
organic phase the so obtained crude material was purified by chromatography on silica gel using ethyl 
acetate as eluent to give the desired products as white powders. 
2-(1-(4-Fluorophenyl)-2-methyl-5-(3-sulfamoylphenyl)-1H-pyrrol-3-yl)-N-(2-hydroxyethyl)acetamide (4a): 
White powder, (0.271 g, 71 % yield); mp 155°C; 1H NMR (400 MHz, DMSO-d6) δ (ppm)= 2.06 (s, 3H, CH3 
pyrrolic), 3.12 (t, J=5.14 Hz, 2H, CO-NH-CH2-CH2-OH), 3.25 (s, 2H, C-CH2-CO), 3.41 (t, J=5.14 Hz, 2H, CO-NH-
CH2-CH2-OH), 4.68 (s broad, 1H, OH), 6.46 (s, 1H, CH pyrrolic), 7.11 (d, J=7.89 Hz, 2H, H aromatic), 7.23-
7.31 (m, 6H, H aromatic and SO2NH2), 7.57 (d, J=7.89 Hz, 2H, H aromatic), 7.83 (s broad, 1H, CONH); 13C-
NMR (100 MHz, DMSO-d6) δ (ppm):171.9, 160.2, 147.0, 144.0, 142.9, 134.6, 128.0, 127.3, 126.2, 121.9, 
121.5, 116.0, 113.7, 66.9, 41.8, 33.9,10.1; IR (KBr): ν˜=3358, 3342, 1752 cm−1; ESI-Mass: m/z 454.12 [M + 
Na]+; HRMS-FAB m/z [M+H]+ calcd for C21H22FN3O4S: 431.1315, found: 431.1318; Anal. calcd for 
C21H22FN3O4S: C 58.46, H 5.14, N 9.74, O 14.83 found: C 58.40, H 5.20, N 9.67, O 14.80.  
2-(1-(3-Fluorophenyl)-2-methyl-5-(3-sulfamoylphenyl)-1H-pyrrol-3-yl)-N-(2-hydroxyethyl)acetamide (4b): 
White powder, (0.256 g, 67% yield); mp 175°C; 1H NMR (400 MHz, DMSO-d6) δ (ppm)= 2.04 (s, 3H, CH3 
pyrrolic), 3.15 (t, J=5.62 Hz, 2H, CO-NH-CH2-CH2-OH), 3.27 (s, 2H, C-CH2-CO), 3.46 (t, J=5.62 Hz, 2H, CO-NH-
CH2-CH2-OH), 4.69 (s broad, 1H, OH), 6.48 (s, 1H, CH pyrrolic), 7.04 (d, J=7.82 Hz, 1H, H aromatic) 7.13 (d, 
J=8.07 Hz, 2H, H aromatic), 7.19-7.33 (m, 4H, H aromatic and SO2NH2), 7.49-7.51 (m, 1H, H aromatic), 7.60 
(d, J=8.07 Hz, 2H, H aromatic), 7.90 (s broad, 1H, CONH); 13C-NMR (100 MHz, DMSO-d6) δ (ppm): 171.3, 
162.9, 142.5, 142.0, 141.6, 133.6, 129.2, 127.8, 126.5, 125.0, 120.9, 116.8, 112.6, 111.9, 106.8, 60.9, 40.8, 
33.2, 9.6; IR (KBr): ν˜=3346, 3300, 1750 cm−1; ESI-Mass: m/z 454.12  [M + Na]+; HRMS-FAB m/z [M+H]+ 
calcd for C21H22FN3O4S: 431.1315, found: 431.1309; Anal. calcd for C21H22FN3O4S: C 58.46, H 5.14, N 
9.74, O 14.83 found: C 58.90, H 5.17, N 9.77, O 14.86. 
In vitro anti-inflammatory studies 
The inhibitory activity of compounds 1-4 against both COX-1 and COX-2 was determined by the 
commercially available COX Inhibitor Screening Assay (Cayman Chemical, Ann Arbor, MI, USA, catalogue no. 
560131), which exploits an enzyme immunoassay to measure PGE2 α produced by stannous chloride 
reduction of PGEH2, derived in turn by reaction between the target enzyme and the substrate, arachidonic 
acid. According to manufacture’s protocol, test compounds (10 μL) were incubated for 10 min at 37 °C with 
assay buffer (0.1 M Tris-HCl, pH 8, 160 μL), Heme (10 μL), and either ovine COX-1 or human recombinant 
COX-2 enzyme solution (10 μM). Arachidonic acid (10 μL) was then added, and the resulting mixture was 
incubated for 2 min at 37°C. Enzyme catalysis was stopped by adding HCl (1M, 10 mL) and the obtained 
PGEH2 were converted to PGE2α with saturated stannous chloride solution (20 μL). Prostanoids were 
finally quantified by EIA and their amount was determined through interpolation from a standard curve. 
The % inhibition of target enzyme by test compounds was calculated by comparing PGE2α produced in 
compound-treated samples with that of the compound-free, control sample. The highly selective COX-2 
inhibitor Dup-697 was used as the reference compound. All the test compounds were dissolved into dilute 
assay buffer, and their solubility was facilitated by using DMSO, whose concentration never exceeded 1% in 
the final reaction mixture. The inhibitory effect of test compounds was routinely estimated at a 
concentration of 10 μM. Results obtained are the mean of at least three determination, carried out in 
triplicate (Table 1). 
 
 
Ex vivo vasorelaxing activity 
All the experimental procedures were carried out following the guidelines of the European Community 
Council Directive 86-609. The effects of the compounds were tested on isolated thoracic aortic rings of 
male normotensive Wistar rats (250–350 g). After a light ether anaesthesia, rats were sacrificed by cervical 
dislocation and bleeding. The aortae were immediately excised, freed of extraneous tissues and the 
endothelial layer was removed by gently rubbing the intimal surface of the vessels with a hypodermic 
needle. Five mm wide aortic rings were suspended, under a preload of 2 g, in 20 mL organ baths, containing 
Tyrode solution (composition of saline in mM: NaCl 136.8; KCl 2.95; CaCl2 1.80; MgSO4 1.05; NaH2PO4 
0.41; NaHCO3 11.9; glucose 5.5), thermostated at 37 °C and continuously gassed with a mixture of O2 
(95%) and CO2 (5%). Changes in tension were recorded by means of an isometric transducer (Grass FTO3), 
connected with a computerised system (Biopac). After an equilibration period of 60 min, the endothelium 
removal was confirmed by the administration of acetylcholine (ACh) (10 lM) to KCl (30 mM)-precontracted 
vascular rings. A relaxation <10% of the KCl-induced contraction was considered representative of an 
acceptable lack of the endothelial layer, while the organs, showing a relaxation P10% (i.e. significant 
presence of the endothelium), were discarded. From 30 to 40 min after the confirmation of the 
endothelium removal, the aortic preparations were contracted by a single concentration of KCl (30 mM) 
and when the contraction reached a stable plateau, 3-fold increasing concentrations of the tested 
compounds (1 nM–10 µM) were added. Preliminary experiments showed that the KCl (30 mM)-induced 
contractions remained in a stable tonic state for at least 40 min. The same experiments were carried out 
also in the presence of a well-known GC inhibitor: ODQ 1 µM which was incubated in aortic preparations 
after the endothelium removal confirmation. The vasorelaxing efficacy was evaluated as maximal 
vasorelaxing response (Emax), expressed as a percentage (%) of the contractile tone induced by KCl 30 mM. 
When the limit concentration 10 µM (the highest concentration, which could be administered) of the 
tested compounds did not reach the maximal effect, the parameter of efficacy represented the 
vasorelaxing response, expressed as a percentage (%) of the contractile tone induced by KCl 30 mM, 
evoked by this limit concentration. The parameter of potency was expressed as pIC50, calculated as 
negative logarithm of the molar concentration of the tested compounds evoking a half reduction of the 
contractile tone induced by KCl 30 mM. The pIC50 could not be calculated for those compounds showing an 
efficacy parameter lower than 50%. The parameters of efficacy and potency were expressed as mean ± 
standard error, for 6-10 experiments. Two-way ANOVA was selected as statistical analysis, P < 0.05 was 
considered representative of significant statistical differences. Experimental data were analysed by a 
computer fitting procedure (software: Graph-Pad Prism 4.0).  
In vivo studies 
All animal manipulations were carried out according to the European Community guidelines for animal care 
(DL 116/92, application of the European Communities Council Directive of 24 November 1986 
(86/609/EEC). The ethical policy of the University of Florence complies with the Guide for the Care and Use 
of Laboratory Animals of the US National Institutes of Health (NIH Publication No. 85-23, revised 1996; 
University of Florence assurance number: A5278-01). Formal approval to conduct the experiments 
described was obtained from the Animal Subjects Review Board of the University of Florence. Experiments 
involving animals have been reported according to ARRIVE guidelines[39]. All efforts were made to 
minimize animal suffering and to reduce the number of animals used. 
Male Swiss albino mice (23–25 g) and Sprague-Dawley or Wistar rats (150–200 g) were used. The animals 
were fed with a standard laboratory diet and tap water ad libitum and kept at 23 (1 °C with a 12 h 
light/dark cycle, light on at 7 a.m.) The analgesic activity of compounds was assessed by performing the 
abdominal constriction test, using mice into which a 0.6% solution of acetic acid (10 mL/kg) had been 
injected intra-peritoneal (ip). The number of stretching movements was counted for 10 min, starting 5 min 
after administration.  
New COX-inhibitor preparation and docking 
All calculations were performed using a blade (Intel-Xeon CPU) running Debian GNU/Linux “Jessie” 8.1 64 
bit operating system. Ligand’s 3D conformations were generated from scratch. Marvin was used for 
drawing, displaying and characterizing chemical structures, Marvin 15.1.12.0, 2015, ChemAxon 
(http://www.chemaxon.com). OpenBabel was used to generate random conformation to run the cross-
docking experiments by Vina COX-2. Docking procedure and detail were the same as previously 
reported[31].  
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